|
| Press Releases |
|
 |
|
| Friday, September 23, 2022 |
|
|
麥迪衛康公佈2022年中期業績 |
| more info >> |
|
|
麦迪卫康公布2022年中期业绩 |
| 中国领先的数字化医疗服务解决方案市场提供商——麦迪卫康健康医疗管理科技股份有限公司(“麦迪卫康”或“公司”，连同其附属公司，统称“集团”) (股份代号：2159)，公布其截至2022年6月30日止六个月(“报告期”或“2022 年上半年”) 未经审计之中期业绩。 more info >> |
|
|
Mediwelcome Announced 2022 Interim Results |
| A China's leading provider of digital medical service solutions - Mediwelcome Healthcare Management & Technology Inc. ("Mediwelcome" or the "Company", and together with its subsidiaries, the "Group") (Stock Code: 2159), announced the unaudited consolidated interim results for the six months ended 30 June 2022 (the "Reporting Period" or the "First half of 2022"). more info >> |
|
| Tuesday, August 31, 2021 |
|
|
麦迪卫康公布2021年中期业绩 |
中国最大的心脑血管疾病综合医疗营销解决方案市场提供商——麦迪卫康健康医疗管理科技股份有限公司(「麦迪卫康」或「公司」，连同其附属公司，统称「集团」)，今天欣然公布其截至2021年6月30日止六个月(「报告期」或「2021年上半年」) 未经审计之中期业绩。
more info >> |
|
|
麥迪衛康公佈2021年中期業績 |
| 中國最大的心腦血管疾病綜合醫療營銷解決方案市場提供商——麥迪衛康健康醫療管理科技股份有限公司(「麥迪衛康」或「公司」，連同其附屬公司，統稱「集團」)，今天欣然公佈其截至2021年6月30日止六個月(「報告期」或「2021年上半年」) 未經審計之中期業績。 more info >> |
|
|
Mediwelcome Announces 2021 Interim Results |
| The largest provider in the Integrated Healthcare Marketing Solutions Market of cardio-cerebral-vascular diseases (CCVDs), Mediwelcome Healthcare Management & Technology Inc. ("Mediwelcome" or the "Company", together with its subsidiaries, the "Group") is pleased to announce the unaudited consolidated interim results for the six months ended 30 June 2021 (the "Reporting Period" or the "First half of 2021"). more info >> |
|
| Thursday, January 7, 2021 |
|
|
Mediwelcome: Bringing High-Quality Medical Service Genes, or an Internet Hospital Upstart? |
| Data from Futu Securities showed that as of 13:00 on January 6, Mediwelcome (02159.HK) was overbuying 47.51 times. Futu expects its subscription multiple to exceed 80 times. Judging from this subscription multiple, this stock is a recent hot stock. more info >> |
|
| Wednesday, January 6, 2021 |
|
|
Mediwelcome: Key Player in the Gold Track, is Forming a Head Leading Advantage |
| Mediwelcome, a domestic provider of comprehensive medical marketing solutions for cardiovascular and cerebrovascular diseases, faces excellent development opportunities. more info >> |
|
|
Mediwelcome: Reasonable valuation with HK listing on track for January 19 |
| Mediwelcome, a domestic provider of comprehensive medical marketing solutions for cardiovascular and cerebrovascular diseases, faces excellent development opportunities. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
International Women's Day: Why Menopause May Be a Missed Cardiovascular Risk Window
Mar 6, 2026 20:00 JST
|
|
|
Xunce (3317.HK) Released Profit Alert: Revenue Doubles, Surpasses Expectations by a Wide Margin, China's Palantir Rises!
Mar 6, 2026 18:23 HKT/SGT
|
|
|
迅策(3317.HK)發佈盈利預告：營收翻翻 大超預期 中國版Palantir崛起！
Mar 6, 2026 18:17 HKT/SGT
|
|
|
迅策(3317.HK)发布盈利预告：营收翻翻 大超预期 中国版Palantir崛起！
Mar 6, 2026 18:00 HKT/SGT
|
|
|
香港實現綠色甲醇首船加注 推動國際航運中心綠色轉型
Mar 6, 2026 15:40 HKT/SGT
|
|
|
香港实现绿色甲醇首船加注 推动国际航运中心绿色转型
Mar 6, 2026 15:31 HKT/SGT
|
|
|
Hong Kong Completes First Green Methanol Bunkering, Driving Green Transformation of Its International Shipping Hub
Mar 6, 2026 15:05 HKT/SGT
|
|
|
Hong Kong Tech Innovators Drive Success at Mobile World Congress and 4YFN Barcelona 2026
Mar 6, 2026 13:08 HKT/SGT
|
|
|
U.S. Polo Assn. Expands Collegiate Partnership Program to Record 70 Teams for 2026 Season
Mar 6, 2026 12:12 HKT/SGT
|
|
|
Anime Tokyo Station: "That Time I Got Reincarnated as a Slime" Special Exhibition, February 21 to May 24, 2026
Mar 6, 2026 10:00 HKT/SGT
|
|
|
TANAKA Develops World's First High-Performance Palladium Hydrogen Permeable Membrane Exhibiting High Hydrogen Purification Performance at Temperatures around 100 degrees C
Mar 5, 2026 22:00 JST
|
|
|
美國馬球協會擴大大學合作計畫 2026賽季隊伍數創紀錄達70支
Mar 5, 2026 20:00 HKT/SGT
|
|
|
美国马球协会扩大大学合作计划，2026赛季参赛队伍创纪录达70支
Mar 5, 2026 20:00 HKT/SGT
|
|
|
Lancaster Resources Announces Resignation of Penny White and the Addition of Rob Heaslop to the Board of Directors
Mar 5, 2026 17:29 HKT/SGT
|
|
|
CMS (867.HK/8A8.SG): Self-Developed INHBE-Targeting siRNA Drug Received IND Approval for Overweight/Obesity
Mar 5, 2026 17:00: JST
|
|
|
|
|
More News >> |
|
|
|
|
|
